Subscribe To

Price Alert Latest News Economic Calendar News

ATOS / Atossa finishes PK run-in cohort enrollment in breast cancer trial

Atossa Therapeutics Inc (NASDAQ:ATOS), which is developing medicines aimed at oncology and breast cancer, revealed that the pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE study, evaluating Endoxifen versus exemestANe GosEreLIn, has now fully enrolled. The Seattle-based clinical-stage biopharma's EVANGELINE study is one of two ongoing Phase 2 trials investigating Atossa's proprietary (Z)-endoxifen as a neoadjuvant treatment, for women with estrogen receptor positive breast cancer. Read More

Demo Live Account See Partner Details

Content Topics

Atossa

Finishes

Run

In

Cohort

Enrollment

Breast

Cancer

Trial

Run in

Stock

ATOS

Posted: Jun 12 2023, 10:52

Author Name: Proactive Investors

ATOS News

By Proactive Investors
October 30, 2023

Atossa Therapeutics' (Z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situ

Atossa Therapeutics Inc (NASDAQ:ATOS)'s selective estrogen receptor modulator (Z)-endoxifen is being evaluated in a Phase 2 study aimed at preventing

By Proactive Investors
September 8, 2023

Atossa Therapeutics' upcoming breast cancer trial results expected to drive stock higher

Analysts at Cantor Fitzgerald have initiated coverage on Atossa Therapeutics Inc (NASDAQ:ATOS) with an ‘Overweight' rating and a $5 price target on

By Proactive Investors
August 23, 2023

Atossa Therapeutics is targeting multiple stages of the breast cancer continuum with oral Endoxifen

Atossa Therapeutics Inc (NASDAQ:ATOS) is targeting three different stages of the breast cancer continuum with its proprietary oral form of Endoxifen,

By Proactive Investors
August 14, 2023

Atossa Therapeutics rides strong momentum in 2Q to clinical advancements and corporate expansion

Atossa Therapeutics Inc (NASDAQ:ATOS) unveiled its second quarter financial results highlighted by a strong balance sheet to support the company in co

By Proactive Investors
July 20, 2023

Atossa Therapeutics gets green light to open enrollment for Phase 2 breast cancer trial in Canada

Atossa Therapeutics Inc (NASDAQ:ATOS) has received what's known as a no objection letter from Health Canada in response to its clinical trial applicat

By Proactive Investors
July 11, 2023

Maxim upbeat on Atossa Therapeutics after recent updates

Analysts at Maxim Group have reiterated a 'buy' rating on Atossa Therapeutics Inc (NASDAQ:ATOS) shares after the biotech recently announced an enroll

By Proactive Investors
July 10, 2023

Atossa Therapeutics provides update on Phase 2 breast density trial enrollment

Atossa Therapeutics Inc (NASDAQ:ATOS) announced that 170 patients have been enrolled across its ongoing Phase 2 Karisma-Endoxifen study of its oral fo

By InvestorPlace
July 6, 2023

3 Penny Stocks to Make Your ‘Get Rich' Dreams Come True

When it comes to potentially profitable penny stocks, some can create unimaginable fortunes for patient investors. Others, not so much.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.